The homeobox (HOX) genes are a highly conserved family of homeodomain-containing transcription factors that specify cell identity in early development and, subsequently, in a number of adult processes including hematopoiesis. The dysregulation of HOX genes is associated with a number of malignancies including acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), where they have been shown to support the immortalization of leukemic cells both as chimeric partners in fusion genes and when overexpressed in their wild-type form. This review covers our current understanding of the role of HOX genes in normal hematopoiesis, AML and ALL, with particular emphasis on the similarities and differences of HOX function in these contexts, their hematopoietic downstream gene targets and implications for therapy.
INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous group of genetically and phenotypically aggressive disorders where the differentiation of hematopoietic progenitor cells is blocked, increasing their self-renewal ability and disturbing the normal regulation of proliferation. 1, 2 In the UK, AML is the most frequent acute leukemia in adults, accounting for 77% of cases. The median age at presentation is 69 years and the male: female ratio is about 5 : 4. The disease is commonly classified by either the FrenchAmerican-British system, or that described by the World Health Organization. The former is based on morphology and maturation stage, and classifies AML into eight groups (M0-M7). The latter is also based on morphology, but also includes immunophenotyping, genetics and clinical manifestations, and classifies AML into four main groups: AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related AML and MDS, or AML that does not fit into any of these groups. Nonrandom chromosomal alterations, such as balanced translocations, monosomies, trisomies, inversion and deletions have been found in the leukemic cells of almost 55% of AML patients, and until recently they were considered to be the most crucial prognostic factors for complete remission, likelihood of relapse and overall survival. 3, 4 Recent advances in molecular diagnosis have resulted in both gene alterations and the dysregulation of specific genes becoming increasingly important as prognostic elements in AML. This has helped to clarify the numerous heterogeneities of AML subsets, particularly AML subsets showing normal karyotype AML 5 , and furthered understanding of the molecular mechanisms of leukemogenesis.
Genetic changes in AML The origin of AML is associated with two distinct genetic changes, referred to as Class I and Class II. Class I consists of mutations that enhance proliferation signal transduction pathways and induce the proliferation of hematopoietic stem cells (HSCs) or precursors and usually affect kinase signaling pathways, such as FLT3, KIT, NRAS/KRAS and JAK/STAT mutations. Class I mutations take place late and cause disease progression. Class II mutations target hematopoietic transcription factor genes leading to a block in myeloid differentiation and conferring the self-renewal ability of hematopoietic precursors. These mutations take place early and initiate the AML disease. [5] [6] [7] One of the most affected and mutated transcription factors are homeobox (HOX) genes.
HOX genes
The HOX genes are a family of homeodomain-containing transcription factors, 8 initially characterized in Drosophila as master regulators of trunk and tail development during embryogenesis. 9 Duplication of the original HOX gene cluster has given rise to 39 genes in mammals, separated into four clusters known as A, B, C and D. [9] [10] [11] These clusters are located on four different chromosomes, HOXA (7p15), HOXB (17q21), HOXC (12q13) and HOXD (2q31). 12 Ancestors of the original gene in each of the clusters are known as paralogs, and generally they show a high degree of sequence similarity as well as functional redundancy (Figure 1 ). 13 The arrangement of HOX genes into clusters allows for enhancer sharing, which enables a precise spatial and temporal coordination of expression during development. The relative regulatory dominance also varies between HOX genes, giving rise to what is often referred to as a 'HOX code', 14 and resulting in the following distinctive criteria: (1) Temporal distribution. The expression of HOX genes starts from the 3 0 end of the cluster and proceeds stepwise towards the 5 0 end. (2) Spatial distribution. The 3 0 most member of the cluster is expressed with a more anterior limit than the next member and each subsequent member has a more posterior limit of expression resulting in an overlapping series of expression domains. (3) Posterior prevalence. In each individual cluster, the function of the posterior gene products is dominant over the more anterior genes. 13 HOX cofactors DNA-binding site studies suggest that HOX proteins have relatively limited selectivity and specificity, and they need cofactor interactions in order to increase both. [15] [16] [17] The most important HOX cofactors are the three amino acid loop extension proteins, which comprise the pre-B-cell leukemia (PBX) and myeloid ectropic insertion site (MEIS) families. 16, 17 These cofactors have crucial roles in development and hematopoiesis. 18 For example, Pbx1 null mice die during the embryonic stage as a result of severe hematopoietic defects, 19 and Meis1-deficient mice fail to generate megakaryocytes, exhibit severe hemorrhaging and likewise die during the embryonic stage. 20 In zebrafish, Meis1 and Pbx contribute to the production of erythropoietic cells and the inhibition of myelopoiesis. 21 Generally, Hox proteins 1-10 bind to Pbx1, 22 whereas Hox proteins 9-13 bind to Meis1. 27 Anterior '3 0 end' HOX genes (HOX1-6) are highly expressed in the most primitive HSCs. Subsequently, the anterior HOX genes are downregulated and posterior '5 0 end' HOX genes are expressed during commitment. 28 HOX genes are highly expressed in the most primitive HSCs and progenitors, while their expression is almost absent in CD34 À cells, which are considered differentiated bone marrow (BM) cells. 26, 28 The analysis of HOX gene expression in human multipotent stem cells and T-cell precursors showed that HOXA genes are prominently expressed during T-cell development, in particular the Abd-HOXA genes including HOXA7-HOXA11, with only HOXB3 and HOXC3 expressed from the other HOX clusters. 29 Gain of function studies The function of HOX genes in normal hematopoiesis has been widely studied using gene expression analysis and knockin or knockout studies in HSCs and early hematopoietic progenitors (Table 1) . Generally the overexpression of a HOX gene leads to an expansion of stem and progenitor cell populations together with a block on differentiation. Notable examples of this include the overexpression of murine Hoxb6, which resulted in the expansion of murine HSCs and myeloid precursors, together with the inhibition of erythropoiesis and lymphopoiesis, 44 and overexpression of murine Hoxb3 that resulted in several hematological abnormalities, such as a block of B-and T-cell differentiation as well as a delay in myeloid precursor proliferation. 37 Overexpression of human HOXC4 resulted in expansion of early and committed myeloid and erythroid progenitors, 47 and knockin of human HOXA5 caused an increase in the number of myeloid progenitors and blocked erythroid differentiation. 30, 31 Likewise, overexpression of HOXA10 in human cord blood or fetal liver CD34 þ hematopoietic progenitors resulted in a significant production of blast cells and myelopoiesis concomitant with a complete block of erythroid differentiation and a severe reduction in B-cell development. 36 Other HOX genes are required for the maintenance of progenitor or stem cell status and promote their proliferation, especially HOXA9 and HOXB4. The former is the most preferentially expressed HOX gene in human CD34
þ HSCs and early hematopoietic progenitors and is subsequently downregulated during differentiation. Murine Hoxa9 overexpression enhances HSC expansion and myeloid progenitor proliferation and, with a long latency, leads to leukemia. 33, 34 In contrast to myeloid progenitors, Hoxa9 overexpression resulted in a partial inhibition of pre-B-cell differentiation, but did not affect T-cell development. 34 Hoxb4 is also highly expressed in HSCs and downregulated during differentiation. 26, 28 Its overexpression in murine and human cell lines results in a remarkable expansion of HSCs in vivo and in vitro without resulting in leukemia or lineage disturbances. 39, 40 Indeed, the self-renewal ability of Hoxb4-transduced HSCs is 20-50-fold greater than untreated cells, and can be increased still further by knocking down Pbx1.
49,50
Loss of function studies In addition to the knockin and overexpression approaches described above, knockdown and deletion studies in murine models and cell lines have also been used to evaluate the role of HOX genes in hematopoiesis. However, owing to the functional redundancy of HOX genes, the results of knockdown assays are sometimes difficult to interpret and do not always reflect the findings of studies where the gene has been overexpressed. For example, it has been found that Hoxb4 null mice exhibit a significant reduction in size and cellularity of hematopoietic organs, such as spleen and liver, and a slight decrease in HSCs and hematopoietic progenitor number without a significant disturbance of lineage commitment. 41, 42 Likewise, Hoxb3 null mice display a notable reduction in B-cell progenitors, and a reduction in BM cellularity, but no significant reduction in B-cell numbers in the spleen. 38 Hoxb3/b4 À / À mice have a greater reduction in HSCs and hematopoietic progenitors, yet no difference in hematopoietic cell commitment. 43 Using quantitative PCR, it has been demonstrated that fetal liver cells (c-Kit þ ) of Hoxb4 null mice expressed other Hoxb genes to a significantly higher level than control cells. 42 Bijl and colleagues 34 found that an individual loss of Hoxb4 or even the complete loss of the Hoxb cluster (b1-b9) did not affect the ability of murine fetal liver HSCs to self-renew. The repopulation and differentiation potential were retained, compared with wild-type control cells. Thus, the Hoxb cluster may not be necessary for hematopoiesis, with members of the other Hox clusters presumably having largely duplicate roles. Analysis of Hox gene expression in fetal liver cells (c-Kit þ Hoxb1-Hoxb9 À / À ), revealed genetic interactions between members of the Hoxa, b and c clusters, whereby these cells exhibited downregulation of all Hoxa genes, except Hoxa13, and upregulation of Hoxc4, Hoxc9 and Hoxc11, also suggesting functional redundancy and complex genetic interactions between Hox genes.
An exception to the general prevalence of functional redundancy amongt the HOX gene family is HOXA9, the most highly expressed HOX family member in HSCs. Hoxa9 À / À mice showed significant deficiencies in myeloid and lymphoid cells concomitant with a significant defect in repopulating ability. These deficiencies include common myeloid progenitors, granulocyte/monocyte precursors, common lymphoid precursors and lymphoid precursors (pro-and pre-B cells, pro-T cells). 35 There is also a corresponding reduction in spleen cellularity and size. Notably, compared with the entire cluster b deficient fetal liver HSCs, Hoxa9 À / À fetal liver HSCs exhibited a more dramatic defect in repopulating ability, 35, 42 and HSCs from Hoxa9/b3/b4 null mice had the same repopulating ability as those from Hoxa9 null mice. 35 Gene knockdown studies have revealed that some additional HOX genes are also essential in normal hematopoiesis. Knockdown of HOXA5 led to an increase in erythroid progenitors and a reduction in the number of myelomonocytic cells, 30, 31 and Hoxa7 null mice showed a reduction in megakaryocytic/erythroid progenitors as well as reticulocytosis and thrombocytopenia. 32 Knockout of Hoxb6 resulted in an increase in early erythroid progenitors in murine BM and fetal liver cells. 45 Likewise, Hoxc3 À / À mice showed a reduction in late erythroid progenitors without affecting the hemoglobinization size, 46 and Hoxc8 deficient mice showed a significant reduction in erythroid, granulocyte and macrophage colony formation potential. 48 Upstream regulators of HOX genes Knockout models of HOX gene upstream regulators have helped to define their role in normal hematopoiesis. Regulators include transcriptional activators such as mixed lineage, myeloid lymphoid leukemia (MLL) and a family of caudal-type HOX transcription factors (CDX1, CDX2 and CDX4). The existence of HOX genes in clusters makes them particularly sensitive to changes in chromosomal organization, and repressors of HOX transcription include genes that mediate this process, most notably members of the The role of HOX genes in normal hematopoiesis and acute leukemia RA Alharbi et al polycomb group. 51 These regulators have crucial roles in normal development and hematopoiesis through the regulation of HOX genes. A number of studies demonstrated that Mll-deficient embryonic bodies and Mll conditional knockout mice showed a dramatic reduction in HSCs and hematopoietic progenitors. In addition, these embryonic bodies and the mice exhibited greatly reduced expression of a number of Hox genes including Hoxa7, Hoxa9, Hoxa10 and other Hoxb and Hoxc genes. 52, 53 Likewise, Cdx compound-deficient zebrafish and murine ESCs showed dysregulation of the embryonic hematopoietic progenitors as well as impaired expression of Hox genes. 54, 55 However, it has been shown that Cdxs are not essential for normal hematopoiesis in adult mice. For example, Cdx4-deficient mice showed minimal hematopoietic defects, though it is highly expressed in wild-type myeloid progenitor cells. 56 In addition, human CDX2 is not expressed in normal HSCs, or in myeloid, B-cell, or T-cell progenitors. [57] [58] [59] HOX downstream target genes in hematopoietic cells The mechanism by which HOX genes regulate hematopoiesis is not yet fully understood. However, genome-wide analyses after experimentally induced changes in HOX gene expression have identified some potential downstream targets. Amongt these are the HOX genes themselves, some of which have been shown to auto-activate their own expression or to crossregulate their neighbors, or their cofactors. HOXA9, HOXA10 and HOXB4 are the most comprehensively studied genes in this respect because of their key roles in normal hematopoiesis and leukemia. It is particularly noteworthy that HOXA9 positively regulates the transcription of other HOX genes including HOXA7 and HOXA10 and its cofactors PBX3 and MEIS1. 60 A summary of HOX downstream target genes is presented in Table 2 .
As described above, HOXA9 is a key regulator of hematopoiesis and behaves as an oncogene in leukemia. It is therefore unsurprising that it activates the transcription of genes known to regulate cell proliferation and survival. For example, Hoxa9 directly activates the Pim1 gene, the product of which enhances proliferation by activating c-Myb, and also exerts an anti-apoptotic effect by phosphorylating and inactivating the BAD protein. 61, 80 C-Myb has also been identified as an indirect transcriptional target of Hoxa9-Meis1 that mediates transformation in Mll-Enl (Eleven nineteen leukemia). 67 Other HOXA9 targets include the oncogene ID2, which is upregulated, and BIM, which encodes an apoptotic factor and is downregulated. 62 HOXA9 also activates the CYBB gene, which encodes Gp91 phox (a phagocyte respiratory burst oxidase protein), and is expressed in differentiated myeloid cells. 63 In mice, Hoxa9 has been shown to directly activate the transcription of the Flt3 gene, which is associated with an unfavorable prognosis of AML, 64 and it also regulates its own cofactor, Meis1, through binding to Meis1 upstream regulator genes cerb1 and pknox1. 65 More proliferative genes have been recently identified as downstream targets for Hoxa9 including Camk2d, Cdk6, Erg, Etv6, Flt3, Foxp1, Gfi1, Kit, Lck, Lmo2, Myb and Sox4. 66 In the same study, it was shown that Hoxa9 downregulates differentiation and inflammation genes including Ifit1, Tlr4, Ccl3, Ccl4, Csf2rb, Ifngr1, Runx1, Cd28 and Cd33. The fusion protein nucleoporin 98 (NUP98-HOXA9) has been found to stimulate the proliferation of HSCs by activating the expression of other HOX genes including HOXA9, HOXA7, MEIS1 and PBX3. It also upregulates a number of leukemogenic transcription factors including EVI1 and MEF2C, and receptor tyrosine kinases including FLT3 and KIT. 68 It is also of note that there are both overlapping opposing functions between the closely related HOXA9 and HOXA10 transcription factors. For example, in a similar manner to Hoxa9, Hoxa10 activates the expression of proliferative genes that result in myeloid progenitor expansion such as Itgb3, Hif, Tgfb2 and Fgf2 by direct binding to their promoters. 69, 70, 81, 82 HOXA10 also activates the transcription of anti-apoptotic genes such as DUSP4, which encodes mitogen-activated protein phosphatase 2. Mitogen-activated protein kinase 2 in turn prevents cell death by downregulating JNK.
71 Hoxa10 decreases erythroid differentiation and megakaryopoiesis by activating Hoxa5 and inactivating Gata1, respectively, 69 and it also induces Cdx4 expression in myeloid cells. 72 Unlike HOXA9, HOXA10 can also exert anti-proliferative effects. For example, in cooperation with its trimeric cofactors, HOXA10 induces P 21 transcription leading to cell cycle arrest and differentiation. 73 It also represses CYBB transcription, 74 thereby acting in an opposing manner to HOXA9. In a fusion form with Nup98, Hoxa10 activates more than 400 genes including the self-renewal genes Flt3, Prnp, Hlf, Jag2.
75
Many HOXB4 target genes have also been identified in three recent studies. 76, 83, 84 Overexpression of Hoxb4 resulted in transcriptional upregulation of Meis1, Dntt, Hlf, Sox4 and Runx2, while it downregulated the transcription of lymphoid specific genes, such as B220, and myeloid-specific genes, such as Hmbs.
76
Some HOXB4 targets seem to vary in a context-dependent manner, for example it has been found to downregulate the transcription of C-MYC in the HL-60 cell line leading to cell differentiation, 77 while it activates c-Myc transcription in murine BM cells. 78 As with HOXA9, Hoxb4 activates the transcription of its neighboring genes, Hoxb2, Hoxb3 and Hoxb5. 41 Hoxb4 also activates the AP-1 complex members Fra-1 and Jun-B, which leads in turn to an increase in the level of cyclin-D1 and a decrease in the level of c-Fos transcription, thereby increasing the proliferation capacity of HSCs. 
HOXA10/ Hoxa10
P21 and DUSP4/ Itgb3, Hlf, Tgfb2, Fgf2, Hoxa5, and Cdx4. CYBB/Gata1. Human/mouse [69] [70] [71] [72] [73] [74] Nup98-Hoxa10 Flt3, Prnp, Hlf and Jag2. Mouse
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HOXB4/Hoxb4
Meis1, Dntt, Hlf, Sox4, Runx2, and C-myc/ Hoxb2, Hoxb3, Hoxb5, Fra-1 and Jun-B.
B220 and HMBS/ C-MYC. Human/mouse 41, [76] [77] [78] [79] Abbreviations: HOX, homeobox; MEIS, myeloid ectropic insertion site; NUP98, nucleoporin 98.
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THE ROLE OF HOX GENES IN ACUTE LEUKEMIA
Numerous studies have now shown that HOX genes can promote the development of AML by forming chimeric fusions with other genes, but more recent work has also shown that their missexpression, in particular their overexpression, is also important in the formation of malignancy.
HOX fusion proteins One of the most frequent fusion partners for HOX genes is NUP98, a member of the nuclear pore family (Figure 2 ). It is localized in the nuclear membrane and functions as a selective transporter for RNA and proteins between the nucleus and cytoplasm. NUP98-HOX fusion proteins have been reported in AML and other leukemias. In AML, NUP98-HOXA9 is associated with a t(7;11) (p15;p15) translocation. 85, 86 There are eight other HOX genes that can be fused with NUP98, including HOXA11 and HOXA13, 87, 88 HOXD11 and HOXD13, 89, 90 and HOXC13. 91 Thus, only the 5 0 end members of each HOX complex have been documented to be fused with NUP98 in AML. However, Hoxb3 has been shown to be a potential leukemogenic partner with Nup98, 92 suggesting that the ability to be a fusion NUP98 partner is not limited to the 5 0 end HOX genes.
Nup98-Hox fusion proteins result in AML with a long latency, around 11-12 months. However, this latency can be reduced to two months by co-overexpression of the Hox cofactor Meis1 and the receptor tyrosine kinase Flt3. [93] [94] [95] FLT3 has an essential role in the regulation of early hematopoietic progenitors growth, and causes increased and uncontrolled self-renewal of these cells through a FLT3 ligand-independent pathway. 96 HOX overexpression in AML HOX genes may also be indirectly involved in AML through chromosomal rearrangements that involve their upstream regulators, such as MLL. MLL fusion proteins constitute about 10% of therapy-related AML and 3% of de novo AML. 97 There are more than 64 translocation partner genes that fuse with the MLL N-terminus. 98 Normally, Mll positively regulates the transcription of Hox genes by maintaining their expression through direct binding to a proximal promoter region. 99 MLL fusion proteins activate HOX gene transcription more efficiently than MLL alone, 97 especially the 5 0 end members of the HOXA cluster, together with their co-activator MEIS1. As a consequence, myeloid differentiation is blocked and proliferation is enhanced. Consistent with this proposed mechanism, it has been reported that MLL-AF9, like NUP98-HOXA9, leads to a block in erythroid/myeloid maturation and to erythroid hyperplasia, 100 and the Mll-Enl fusion protein requires Hoxa7 and Hoxa9 for efficient immortalization of myeloid precursor cells. 101 Conversely, a number of studies demonstrated that the expression of HOXA genes is not crucial for MLL leukemogenesis, yet their expression affects disease phenotype. For instance, Hoxa7 and Hoxa9 influence AML latency and phenotype; yet they are not essential to initiate Mll-Gas7-mediated leukemogenesis. 32 Furthermore, suppression of HOXA9 expression in cells with a chimeric MLL-AF9 gene reduces the survival of leukemic cells and changes the disease phenotype, but it does not affect AML initiation. 60 The dysregulation of another regulator of HOX genes, the CDX gene family, has also been shown to drive the development of AML. CDX2 is expressed in the majority of AML cases (90%), but not in normal adult hematopoiesis, and Cdx2-elevated expression leads to AML with only a short latency period. 57 In contrast, the closely related CDX4 gene is expressed in 25% of AML cases, and in normal adult hematopoiesis, and Cdx4 overexpression in murine whole BM results in AML but only with a long latency period. 102 This latency can be accelerated in mice through cooperation of Meis1 which results in the overexpression of a number of Hox genes including Hoxa6, Hoxa7, Hoxa9, Hoxb4, Hoxb8 and Hoxc6.
103 Cdx2 expression alone is sufficient to drive the upregulation of a related set of HOX genes, 58 demonstrating the importance of the Cdx family in the dysregulation of Hox genes during AML.
The dysregulation of HOX gene expression is also associated with the nucleophosmin 1 (NPM1) mutation. NPM1 is a chaperone protein that shuttles between the nucleus and cytoplasm, although its predominant localization is in the nucleus.
104 NPM1 has a crucial role in several biological processes, such as ribosome biogenesis, genomic stability and cell cycle progression. In adult AML, NPM1 mutation is the most common genetic aberration, reported in about 35% of all adult AML and approximately in 45-55% of normal karyotype AML. [105] [106] [107] In pediatric AML, NPM1 mutations are significantly less common, occurring in 8-10% of cases, and in about a quarter of normal karyotype cases. 108, 109 The relocation of NPM1 into the cytoplasm (NPMc þ ) occurs only in AML. 110 This relocation causes upregulation of a number of HOX genes, some of which are similar to those seen in AML initiated by a MLL chimeric gene fusion, while some are distinct. Thus for example HOXA4, HOXA6, HOXA7, HOXA9, HOXB9 and MEIS1 are overexpressed in both contexts, while HOXB2, HOXB3, HOXB5, HOXB6 and HOXD4 are upregulated in NPMc þ AML only. 111 It has been reported that activation of a humanized Npm1 allele led to overexpression of Hoxa5, Hoxa7, Hoxa9 and Hoxa10, induction of HSC self-renewal and the expansion of myelopoiesis. 112 The exact mechanism of the association between the NPM1 mutation and the upregulation of HOX genes is still unclear. A possible explanation is that NPM1 directly disturbs the expression of HOX genes, or alternatively, that NPM1 mutations arrest the differentiation of early hematopoietic progenitors in which HOX expression is upregulated. 104 HOX gene dysregulation in acute lymphoid leukemia The dysregulation of HOX genes has also been reported in acute lymphoid leukemia (ALL) including both B-and T-precursor ALL (B-ALL and T-ALL), especially when MLL translocations are involved. For example, human HOXA9, HOXA10 and HOXC6, and their cofactor MEIS1 were upregulated in both MLL-ENL T-ALL and MLL B-ALL. 113 Human HOXA9 and MEIS1, and murine Hoxa5, Hoxa9 and Meis1 were likewise upregulated in MLL-AF4 B-ALL. 114, 115 A common signature of MLL rearrangements in AML and ALL is the overexpression of HOXA genes including HOXA3, HOXA5, HOXA7,  HOXA9 and HOXA10 . 116 In addition, HOX genes can be involved in T-ALL through other translocations such as CALM-AF10 T-ALL, where human HOXA5, HOXA9, HOXA10 and MEIS1 are overexpressed. 117 HOXA proteins can also form chimeric fusion proteins with T-cell receptor (HOXA-TCR) in T-ALL, which results in the global overexpression of HOXA genes. 118, 119 Surprisingly, the aberrant expression of CDX2 in ALL, an upstream regulator of HOX genes, is not correlated with HOX gene dysregulation. 120 HOX genes as prognostic markers HOX gene expression has become an important prognostic factor in AML. Overexpression of HOX genes is associated with an intermediate/unfavorable cytogenetic subset of AML. For example, among 6817 genes that have been investigated in AML patients, the single gene correlated with the worst outcome and relapse of disease as well as short survival was HOXA9. 121 Correspondingly, low HOXA9 expression was found to correlate with the best outcome and response to therapy. 122 It is also noteworthy that low expression of HOXA4 and MEIS1 are also favorable predictors for AML patient outcome. 123 The global levels of HOX expression also seem to reflect the outcome of disease, possibly reflecting the functional redundancy exhibited by many of the HOX genes. Thus, the highest levels of HOX genes are seen in FLT3 mutation cases, which have unfavorable outcomes, and generally the HOX genes are expressed only at a very low level in favorable subsets of AML.
FUTURE DIRECTIONS
Although recent work has established the importance of HOX genes in the development of AML, it is still not clear exactly what the functions of these genes are beyond a general inhibition of differentiation and an increase in cell proliferation. This lack of precise mechanistic knowledge for individual HOX genes may be owing to the functional redundancy showed by many members of this family, making the knockdown of single HOX genes generally difficult to interpret, and it may also help to explain the contrast in gene knockin and knockout results. In myeloma and some solid malignancies this has been addressed by targeting the HOX genes as a group by antagonizing their interactions with the PBX cofactor using the peptide inhibitor HXR9. [124] [125] [126] [127] [128] A similar approach may be useful in AML for addressing redundant functions of HOX genes. HXR9 is cytotoxic to cells, predominantly through the induction of apoptosis, which in turn depends upon a rapid increase in expression of c-Fos. [124] [125] [126] [127] [128] [129] It seems likely that AML would also be sensitive to killing by HXR9, and indeed it may be that the HOX genes could represent a useful therapeutic target, especially in AMLs that show high levels of HOX expression and a correspondingly poor prognosis.
